NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 15 September, 09:30am

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair, Chair of Topic 1) Present for all items
3. Laura Bojke Present for all items
4. Maria Brezitski Present for items 1 to 5.1.3
5. Professor Iolo Doull Present for all items
6. Professor Nicholas Latimer Present for all items
7. Professor David McAllister Present for all items
8. Dr Rhiannon Owen Present for items 1 to 5.1.3
9. Anna Pracz Present for items 1 to 5.1.3
10. Gabriel Rogers  Present for all items
11. Professor Toby Smith Present for items 1 to 5.1.3
12. Mary Weatherstone Present for all items
13. Nigel Westwood Present for all items

NICE staff present

Richard Diaz, Associate Director Items 5 to 5.3.2

Janet Robertson, Associate Director Items 1 to 4.2.2

Daniel Davies, Project Manager Items 5 to 5.3.2

Thomas Feist, Project Manager Items 1 to 4.2.2

Lorna Dunning, Heath Technology Assessment Adviser Items 1 to 4.2.2

Emma Douch, Heath Technology Assessment Analyst Items 5 to 5.3.2

Summaya Mohammad, Heath Technology Assessment Analyst Items 1 to 4.2.2

Heather Stegenga, Heath Technology Assessment Analyst Items 5 to 5.1.3

Anna Willis, Heath Technology Assessment Analyst Items 1 to 4.2.2

Emily Eaton-Turner, Technical Analyst, Commercial Risk Assessment Items 1 to 4.2.2

Hugh McGuire, Senior Scientific Adviser Items 1 to 4.1.3

Nicola Bodey, Resource Impact Items 1 to 4.1.3

Anna Sparshatt, Senior Medical Editor Items 1 to 4.2.2

Ruth Melville, Senior Medical Editor Items 5 to 5.3.2

Mandy Tonkinson, Public Involvement Adviser, PIP Items 1 to 4.1.3 & 5 to 5.1.3

Ella Fitzpatrick, Coordinator, PIP Items 1 to 4.2.2

Emma Gordon, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Laura Kelly, Administrator, COT Present for all items

Ayla Hudson, Apprentice, Planning & Ops Present for items 5 to 5.1.3

External assessment group representatives present

Katie Ren, ScHARR Items 1 to 4.1.3

Sarah Davis, ScHARR Items 1 to 4.1.3

Robert Wolff, [Kleijnen Systematic Reviews Ltd](http://niceplan2/Appraisals_TestLive/Stakeholders17.aspx?ACID=1416) (KSR) Items 5 to 5.2.1

Thea Van Asselt, [Kleijnen Systematic Reviews Ltd](http://niceplan2/Appraisals_TestLive/Stakeholders17.aspx?ACID=1416) (KSR) Items 5 to 5.2.1

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Lead, NHS England, present for all items

Dr Stephen Allen, Patient Expert and Chairman of Tackle Prostate Cancer, items 1 to 4.1.3

Dr Amit Bahl, Consultant Oncologist, University Hospitals Bristol NHS Foundation Trust, items 1 to 4.1.3

Dr Amarnath Challapalli, Consultant Clinical Oncologist, University Hospitals Bristol NHS Foundation Trust, items 1 to 4.1.3

Professor Sabina Dizdarevic, Principal Lead Consultant in Imaging and Nuclear Medicine, University Hospital Sussex NHS Foundation NHS Trust, items 1 to 4.1.3

Peter Isard, Patient Expert, nominated by Tackle Prostate Cancer, items 1 to 4.1.3

Dr Sam Amin, Lead Consultant Paediatric Neurologist, Lead Consultant Paediatric Neurologist, items 5 to 5.1.3

Lisa Suchet, Patient Expert, nominated by Tuberous Sclerosis Association , items 5 to 5 Dr Pooja Takhar, Head of Research and Policy, Tuberous Sclerosis Association, items 5 to 5.13.

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from committee members.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 10 August.

### Appraisal of Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Nicholas Latimer an indirect financial interest, as he was paid to give Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods. Novartis are the manufacturer (October 2021.) Professor Latimer also declared a non-financial professional and personal interest as he is also a member of the ScHARR team for a consultancy project involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumours. Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis are the manufacturer. It was agreed that these declarations would not prevent Professor Latimer from being participating in the meeting.
* Professor David McAllister declared a non-financial professional and personal interest, as part of the research he conducts uses data provided by sponsors (or competitors) provided via public trial repositories. Access is managed via an independent steering committee and neither I nor my organisation receive any funds from the trial companies for the work done. It was agreed that these declarations would not prevent Professor McAllister from participating in the meeting.
* Professor Amit Bahl declared various indirect financial interests, having sat on advisory boards for Advisory boards for Sanofi, Astellas, BMS, Janssen, Pfizer, Bayer, EUSA, AAA (Novartis). Professor Bahl has also sat on advisory boards for Accord, alongside having received sponsorship for meetings and educational lectures. It was agreed that these declarations would not prevent Professor Bahl from providing expert advice to the committee.
* Dr Amarnath Challapalli declared an indirect financial interest as he has received speaker fees and honoraria from Janssen, Sanofi, Bayer and Astellas. Dr Challapalli was also part of ERG review panel for Lu-PSMA and was responsible for starting the EMES programme for Lu-PSMA at the University Hospitals Bristol NHS Foundation Trust. It was agreed that these declarations would not prevent Dr Challapalli from providing expert advice to the committee.
* Professor Sabina Dizdarevic declared indirect financial interests due to having been a member of an advisory board for Novartis, alongside receiving educational platform consultancy agreement for PSMA treatment, and receiving speaker fees from GE and Bayer. Prior to the meeting, Professor Dizdarevic also declared an indirect interest, having been a BNSM Council member and Research Lead Chair of the ICSCNM, RCR/RC. It was agreed that these declarations would not prevent Professor Dizdarevic from providing expert advice to the committee.
  + 1. The Chair - Dr Baljit Singh - led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team – Professor David McAllister (Clinical), Gabriel Rogers (Cost) and Nigel Westwood (Lay)
  1. Part 2 - Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10730>

### Appraisal of Cannabidiol for treating seizures caused by tuberous sclerosis complex [ID1416]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from GW Pharmaceuticals.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor David McAllister declared a non-financial professional and personal interest, as part of the research he conducts uses data provided by sponsors (or competitors) provided via public trial repositories. Access is managed via an independent steering committee and neither I nor my organisation receive any funds from the trial companies for the work done. It was agreed that these declarations would not prevent Professor McAllister from being participating in the meeting.
* Dr Pooja Takher declared a direct financial interest as her organisation has received grants and honoraria from GW Pharmaceuticals and Norvartis in the past 12 months. Prior to the meeting, Dr Takher declared a professional and personal interest, as she is listed as a co-author on two unpublished papers setting out the findings from an online QoL survey about impact of TSC on carers organised by GW Pharma Ltd. It was agreed that these declarations would not prevent Dr Takher from providing expert advice to the committee.
  + 1. The Chair - Dr Charles Crawley - led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team: Iolo Doull (Clinical), Laura Bojke (Cost) and Nigel Westwood (Lay)
  1. Part 2a – Closed session (members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/awaiting-development/gid-ta10840>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 13 October and will start promptly at 09:30am.